How Agile Construction Practices Can Help Bring New Drugs And Vaccines To Market

By Damien Galloghly

Since the onset of the global pandemic, the life sciences industry has been devoted to developing and rolling out reliable vaccines as quickly as possible. Foundational research on similar illnesses have been ongoing for decades, with companies worldwide already having a degree of infrastructure in place to develop and produce a COVID-19 vaccine.

With the previous U.S. administration dedicating billions of dollars specifically to domestic vaccine research and production, small-to-midsize American manufacturers have rushed to compete with the existing capacities of international competitors.

By implementing flexibility in agile construction, adopting predictive data analytics, and referencing benchmarking data, contractors can help with the swift rollout of COVID vaccines while keeping up with global demand for new treatments.